FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 640 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline August 28, 2025 News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... June 20, 2020 Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto June 18, 2020 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... January 27, 2020 Load more HOT NEWS Breast Cancer Patient Takes Silly Pictures During Each Radiation Treatment to... Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA... Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers
